# GRIN2D Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *GRIN2D* gene encodes the GluN2D subunit of the NMDAR, a ligand-gated ion channel with restricted expression in the diencephalon, midbrain, and spinal cord, characterized by slow channel kinetics and distinct pharmacological properties.
- Germline mutations in *GRIN2D* cause autosomal dominant neurodevelopmental disorders, including epileptic encephalopathy and intellectual disability, with gain-of-function mutations in the transmembrane domain (e.g., p.Val667Ile) leading to severe early-onset epilepsy due to reduced Mg²⁺ block.
- Somatic *GRIN2D* mutations, particularly at the p.Arg668Cys and p.Val667Ile hotspots, are implicated in neuroblastoma and glioblastoma, potentially promoting tumor cell proliferation and invasion through calcium-dependent signaling pathways like PI3K/Akt and NF-κB.
- Viral pathogens such as HIV-1 (gp120) and Zika virus can modulate GluN2D function, contributing to neurocognitive disorders and impaired neurogenesis, respectively, by altering calcium influx and receptor expression.
- Therapeutic strategies for *GRIN2D*-related disorders include memantine for gain-of-function mutations to reduce excessive NMDAR activity, and investigational approaches like allele-specific antisense oligonucleotides (ASOs) for targeted mRNA degradation.

---

## Executive Summary & Key Metadata

The *GRIN2D* gene encodes the GluN2D subunit of the N-methyl-D-aspartate receptor (NMDAR), a ligand-gated ion channel central to excitatory glutamatergic neurotransmission. Unlike the more abundant GluN2A and GluN2B subunits, GluN2D exhibits a restricted expression profile, predominantly in the diencephalon, midbrain, and spinal cord, and is characterized by slower channel kinetics and distinct pharmacological properties. This manual provides an exhaustive technical reference covering the genomic architecture, protein domain organization, signaling mechanisms, pathogenic mutation spectrum, pharmacogenomic relevance, and bioinformatic resources for GRIN2D.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | GRIN2D |
| UniProt Accession | O15399 |
| Representative PDB ID | 6IRA (heterotetrameric GluN1/GluN2D amino-terminal domain) |
| Chromosomal Locus | 19q13.33 |
| Primary Molecular Function | NMDA receptor subunit; ligand-gated ion channel; excitatory postsynaptic potential generation |
| Disease & Pathology Associations | GRIN2D-related neurodevelopmental disorder (GRIN2D-NDD); epileptic encephalopathy; intellectual disability; schizophrenia susceptibility; potential oncogenic roles in neuroblastoma and glioblastoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *GRIN2D* gene is located on the long arm of chromosome 19 at cytogenetic band 19q13.33. The genomic span covers approximately 43.5 kilobases (kb) on the plus strand, from position 48,855,000 to 48,898,500 (GRCh38/hg38 assembly). The gene comprises 13 exons and 12 introns, with the coding sequence (CDS) spanning 4,032 nucleotides that translate into a protein of 1,343 amino acids (canonical isoform).

The promoter region of *GRIN2D* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to dynamic DNA methylation, which has been demonstrated to regulate tissue-specific expression. In non-neuronal tissues, the promoter is hypermethylated, leading to transcriptional silencing; in neuronal tissues, partial demethylation permits basal expression. The promoter also contains multiple GC-box elements that serve as binding sites for the transcription factor Specificity Protein 1 (Sp1) and Specificity Protein 4 (Sp4), both of which are required for basal transcriptional activity.

### 1.2 Transcription Factor Binding and Enhancer Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals several conserved transcription factor binding sites within the proximal promoter and first intron:

- **Sp1/Sp4**: Bind to GC-boxes at positions -150 to -120 and -80 to -50 relative to the TSS. These factors recruit the basal transcription machinery and maintain open chromatin conformation.
- **Neuron-Restrictive Silencer Factor (NRSF/REST)**: A binding site is located in intron 1 at position +1,200. REST binding represses *GRIN2D* expression in non-neuronal tissues, contributing to its neuronal specificity.
- **cAMP Response Element-Binding Protein (CREB)**: A CRE site at position -200 responds to calcium influx and cAMP signaling, providing a mechanism for activity-dependent regulation of GluN2D expression.
- **Nuclear Factor-kappa B (NF-κB)**: A binding site at position -350 mediates inflammatory cytokine-induced upregulation in pathological states.

Enhancer elements have been identified via Hi-C and enhancer-promoter interaction maps. A putative enhancer located 15 kb downstream of the gene (at chr19:48,870,000-48,872,000) shows strong interaction with the *GRIN2D* promoter in midbrain tissues, as confirmed by promoter capture Hi-C. This enhancer is marked by H3K27ac and H3K4me1 histone modifications and contains binding sites for the midbrain-specific transcription factor PITX3, which may explain the elevated expression of GluN2D in dopaminergic neurons of the substantia nigra.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *GRIN2D* generates multiple transcript variants, although the functional significance of most remains incompletely characterized:

- **Isoform 1 (Canonical)**: 13 exons, 1,343 amino acids. This is the predominant isoform in the brain and the reference sequence for all structural and functional studies.
- **Isoform 2**: Retains intron 4, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role by sequestering splicing factors.
- **Isoform 3**: Skips exon 11, resulting in an in-frame deletion of 45 amino acids within the C-terminal domain (CTD). This isoform lacks a portion of the PDZ-binding motif interaction region and exhibits altered synaptic anchoring. Expression is enriched in the spinal cord.
- **Isoform 4**: Uses an alternative promoter in intron 2, producing a truncated N-terminus lacking the signal peptide. This isoform is retained intracellularly and may exert dominant-negative effects on surface receptor assembly.

The 3' untranslated region (UTR) of *GRIN2D* is unusually long (~3.5 kb) and contains multiple AU-rich elements (AREs) and binding sites for microRNAs, including miR-132 and miR-212. These miRNAs are activity-regulated and repress GluN2D translation, providing a post-transcriptional brake on receptor expression during synaptic plasticity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The GluN2D protein is a type I transmembrane protein with a modular architecture shared among all NMDAR subunits. The protein is organized into four major domains, proceeding from the N-terminus to the C-terminus:

1. **Amino-Terminal Domain (ATD)**: Residues 1–400
2. **Ligand-Binding Domain (LBD)**: Residues 401–650 (S1) and 780–850 (S2)
3. **Transmembrane Domain (TMD)**: Residues 651–779 (M1, M2, M3, M4 segments)
4. **C-Terminal Domain (CTD)**: Residues 851–1,343

### 2.2 Amino-Terminal Domain (ATD)

The ATD adopts a clamshell-like bi-lobed structure composed of two subdomains (R1 and R2) connected by a flexible hinge. In GluN2D, the ATD lacks the high-affinity allosteric modulator binding sites found in GluN2A (which binds ifenprodil) and GluN2B (which binds zinc with high affinity). Instead, the GluN2D ATD contains a low-affinity zinc binding site (Kd ~ 20 μM) that mediates voltage-independent inhibition. The ATD also contributes to subunit assembly specificity; heterodimerization between GluN1 and GluN2D ATDs is driven by hydrophobic interactions at the R1-R1 interface.

Cryo-electron microscopy (cryo-EM) structures of the GluN1/GluN2D receptor (PDB: 6IRA) reveal that the GluN2D ATD adopts a more open conformation compared to GluN2A/B, which correlates with its lower sensitivity to allosteric inhibitors and its distinct desensitization kinetics.

### 2.3 Ligand-Binding Domain (LBD)

The LBD is formed by two discontinuous segments: S1 (residues 401–650) and S2 (residues 780–850). These segments fold into a bilobed structure resembling a Venus flytrap, with the agonist binding site located in the cleft between the D1 and D2 lobes. For GluN2D, the endogenous agonist is L-glutamate, which binds with an EC50 of approximately 0.4–0.8 μM. The binding pocket is formed by:

- **D1 lobe residues**: Arg-493, Ser-495, Thr-497, and Asp-510, which form hydrogen bonds with the α-carboxylate and α-amino groups of glutamate.
- **D2 lobe residues**: Tyr-761, Ser-763, and Thr-765, which coordinate the γ-carboxylate of glutamate.

The GluN2D LBD exhibits a higher affinity for glutamate compared to GluN2A (EC50 ~ 2 μM) but a lower affinity than GluN2C (EC50 ~ 0.3 μM). The closure of the LBD upon agonist binding triggers a conformational change that is transmitted to the TMD via a conserved linker region, ultimately opening the ion channel pore.

### 2.4 Transmembrane Domain (TMD)

The TMD consists of three membrane-spanning helices (M1, M3, M4) and a re-entrant pore loop (M2). The M2 loop lines the ion channel pore and contains the Q/R/N site (asparagine at position 615 in GluN2D), which is critical for calcium permeability and magnesium block. Unlike AMPA receptors, which undergo RNA editing at this site, the NMDAR Q/R/N site is not edited; the asparagine residue is constitutively present.

The M3 helix contains the channel gate, formed by a constriction at the level of the SYTANLAAF motif (residues 640–648). This motif is highly conserved across all ionotropic glutamate receptors and undergoes a rotational movement during channel opening. The M4 helix faces the lipid bilayer and interacts with membrane cholesterol, which modulates channel function.

The TMD also contains the binding site for the co-agonist glycine/D-serine on the GluN1 subunit, which is required for channel opening. The GluN2D TMD contributes to the negative allosteric modulation by phenylethanolamines and the use-dependent block by MK-801.

### 2.5 C-Terminal Domain (CTD)

The CTD of GluN2D is the longest among all NMDAR subunits (493 amino acids) and is largely intrinsically disordered. Despite lacking stable tertiary structure, the CTD contains multiple short linear motifs (SLiMs) that mediate protein-protein interactions:

- **PDZ-binding motif** (residues 1339–1343: ESDV): Binds to PDZ domain-containing scaffolding proteins, including PSD-95, SAP102, and PSD-93. This interaction anchors the receptor at synapses and links it to downstream signaling complexes.
- **Calmodulin-binding domain** (residues 1,050–1,090): Mediates calcium-dependent inactivation of the receptor.
- **Phosphorylation sites**: Multiple serine and threonine residues are substrates for protein kinase C (PKC; Ser-1,290, Ser-1,310), protein kinase A (PKA; Ser-1,160), and CaMKII (Ser-1,280). Phosphorylation modulates receptor trafficking, surface expression, and channel open probability.
- **Clathrin adaptor binding motif** (residues 1,200–1,220): Interacts with AP-2, promoting clathrin-mediated endocytosis and receptor internalization.

### 2.6 Quaternary Structure

Functional NMDARs are obligate heterotetramers, typically composed of two GluN1 subunits and two GluN2 subunits. The GluN1/GluN2D receptor can assemble as either a di-heteromeric (2 GluN1 + 2 GluN2D) or tri-heteromeric (2 GluN1 + 1 GluN2D + 1 GluN2A/B/C) complex. The subunit arrangement follows a 1-2-1-2 pattern around the central pore, with the GluN1 subunits positioned diagonally opposite each other.

The cryo-EM structure of the GluN1/GluN2D receptor (PDB: 6IRA) at 3.8 Å resolution reveals that the GluN2D ATD sits higher above the membrane plane compared to GluN2A, creating a more open extracellular vestibule. This structural difference underlies the distinct pharmacological profile of GluN2D-containing receptors, including their lower sensitivity to competitive antagonists and their resistance to ifenprodil.

> **[Interactive 3D Protein Visualizer: Load GRIN2D (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15399)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ion Channel Function and Electrophysiological Properties

The GluN1/GluN2D receptor is a non-selective cation channel permeable to Na⁺, K⁺, and Ca²⁺. Activation requires simultaneous binding of two agonists: glutamate to the GluN2D subunit and glycine (or D-serine) to the GluN1 subunit. The channel is blocked by extracellular Mg²⁺ in a voltage-dependent manner, with the block relieved upon membrane depolarization.

Electrophysiological characterization of recombinant GluN1/GluN2D receptors reveals several distinctive properties:

- **Slow activation kinetics**: Time-to-peak of ~50–100 ms, compared to ~10 ms for GluN2A-containing receptors.
- **Slow deactivation kinetics**: Deactivation time constant of ~400–500 ms, producing prolonged excitatory postsynaptic currents (EPSCs).
- **Low open probability**: Maximal open probability (Po) of ~0.1, compared to ~0.5 for GluN2A.
- **Weak voltage-dependent Mg²⁺ block**: The Mg²⁺ IC50 at -60 mV is ~10 μM, compared to ~1 μM for GluN2A, making GluN2D receptors more permissive to calcium influx at hyperpolarized potentials.
- **Minimal desensitization**: GluN2D-containing receptors show little desensitization in the continued presence of agonist, contributing to tonic NMDA currents.

These properties position GluN2D as a mediator of tonic, extrasynaptic NMDA currents rather than fast phasic synaptic transmission. In the substantia nigra pars compacta, GluN2D contributes to the slow NMDA component of excitatory postsynaptic potentials in dopaminergic neurons, modulating pacemaker activity and burst firing.

### 3.2 Downstream Signaling Cascades

Calcium influx through GluN2D-containing receptors activates multiple intracellular signaling pathways:

**1. CaMKII Pathway**: Calcium-calmodulin-dependent protein kinase II (CaMKII) is recruited to the receptor via direct binding to the GluN2D CTD. Upon activation, CaMKII phosphorylates downstream targets including AMPA receptors (GluA1 at Ser-831), enhancing their conductance and promoting synaptic potentiation. However, the low open probability of GluN2D receptors results in weaker CaMKII activation compared to GluN2A/B-containing receptors.

**2. MAPK/ERK Pathway**: Calcium influx activates Ras, which triggers the Raf-MEK-ERK cascade. ERK translocates to the nucleus and phosphorylates transcription factors including Elk-1 and CREB. This pathway is implicated in activity-dependent gene expression and long-term memory formation.

**3. PI3K/Akt Pathway**: NMDAR activation recruits PI3K to the membrane, generating PIP3 and activating Akt. Akt phosphorylates multiple substrates, including the pro-apoptotic protein Bad, promoting cell survival. GluN2D-containing receptors are particularly effective at activating this pathway due to their extrasynaptic localization, which couples them to distinct signaling complexes.

**4. nNOS/NO Pathway**: Calcium influx through NMDARs activates neuronal nitric oxide synthase (nNOS), which is anchored to the receptor via PSD-95. Nitric oxide (NO) acts as a retrograde messenger, diffusing to presynaptic terminals and modulating neurotransmitter release. GluN2D-containing receptors in the striatum couple to nNOS, contributing to NO-mediated signaling in this region.

### 3.3 Protein-Protein Interaction Network

The GluN2D CTD serves as a scaffold for a diverse array of interacting proteins, as cataloged in BioGRID and STRING databases:

| **Interactor** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| PSD-95 (DLG4) | PDZ-binding motif (ESDV) | Synaptic anchoring; coupling to nNOS and SynGAP |
| SAP102 (DLG3) | PDZ-binding motif | Trafficking and synaptic delivery |
| PSD-93 (DLG2) | PDZ-binding motif | Synaptic clustering |
| Calmodulin | Calmodulin-binding domain | Calcium-dependent inactivation |
| AP-2 (adaptor complex) | Clathrin-binding motif | Endocytosis and internalization |
| CaMKII | CTD (multiple sites) | Phosphorylation and signaling |
| PKC | CTD (Ser-1,290, Ser-1,310) | Phosphorylation; modulation of channel function |
| PKA | CTD (Ser-1,160) | Phosphorylation; modulation of surface expression |
| nNOS | Via PSD-95 | NO production |
| SynGAP | Via PSD-95 | Ras GTPase-activating protein; synaptic plasticity |
| Shank1 | Via PSD-95 | Scaffolding at postsynaptic density |
| Homer1 | Indirect via Shank | Metabotropic glutamate receptor coupling |

### 3.4 Regulatory Feedback Loops

GluN2D expression is subject to multiple autoregulatory feedback mechanisms:

**Activity-Dependent Transcriptional Regulation**: Calcium influx through NMDARs activates CREB, which binds to the CRE site in the *GRIN2D* promoter. This creates a positive feedback loop where receptor activation increases receptor expression. Conversely, prolonged activation triggers the expression of the transcriptional repressor REST, which binds to the intronic NRSF site and suppresses transcription, providing negative feedback.

**MicroRNA-Mediated Regulation**: The activity-regulated miRNAs miR-132 and miR-212 target the 3' UTR of *GRIN2D* mRNA, promoting its degradation. This provides a rapid post-transcriptional mechanism to limit receptor expression following periods of heightened activity.

**Receptor Internalization**: Activation of PKC phosphorylates the GluN2D CTD, promoting AP-2 binding and clathrin-mediated endocytosis. This reduces surface receptor density, limiting calcium influx and preventing excitotoxicity.

**Calcium-Dependent Inactivation**: Calmodulin binding to the CTD induces a conformational change that reduces channel open probability, providing a fast negative feedback on calcium influx.

### 3.5 Mermaid Diagram: GRIN2D Signaling Cascade

```mermaid
sequenceDiagram
    participant Pre as "Presynaptic Terminal"
    participant Syn as "Synaptic Cleft"
    participant GluN2D as "GluN1/GluN2D Receptor"
    participant Ca as "Intracellular Ca²⁺"
    participant CaM as "Calmodulin"
    participant CaMKII as "CaMKII"
    participant ERK as "MAPK/ERK"
    participant CREB as "CREB"
    participant Nucleus as "Nucleus"
    Pre->>Syn: Glutamate release
    Syn->>GluN2D: Glutamate binding (EC50 ~0.5 μM)
    Note over GluN2D: Glycine co-agonist required
    GluN2D->>Ca: Ca²⁺ influx (slow kinetics)
    Ca->>CaM: Ca²⁺/CaM complex formation
    CaM->>GluN2D: Calmodulin binding (inactivation)
    Ca->>CaMKII: CaMKII activation
    CaMKII->>GluN2D: Phosphorylation (Ser-1280)
    Ca->>ERK: Ras-MEK-ERK cascade
    ERK->>Nucleus: ERK nuclear translocation
    Nucleus->>CREB: CREB phosphorylation (Ser-133)
    CREB->>Nucleus: Transcriptional activation
    Nucleus->>GluN2D: Increased GRIN2D expression
    Note over GluN2D: Negative feedback via REST and miR-132
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 GRIN2D-Related Neurodevelopmental Disorder (GRIN2D-NDD)

Germline mutations in *GRIN2D* cause a rare autosomal dominant neurodevelopmental disorder characterized by epileptic encephalopathy, intellectual disability, hypotonia, and movement disorders. The disorder is part of the broader group of GRINopathies, which also include mutations in *GRIN1*, *GRIN2A*, *GRIN2B*, and *GRIN2C*.

### 4.2 Functional Classification of Mutations

Mutations in *GRIN2D* are classified based on their functional effect on receptor activity:

**Gain-of-Function (GoF) Mutations**: These mutations increase channel activity, typically by enhancing agonist potency, increasing open probability, or reducing Mg²⁺ block. GoF mutations are associated with severe early-onset epileptic encephalopathy.

**Loss-of-Function (LoF) Mutations**: These mutations reduce or abolish receptor function, either by impairing protein folding, trafficking, or ion permeation. LoF mutations are associated with intellectual disability and autism spectrum disorder without severe epilepsy.

### 4.3 Recurrent Pathogenic Variants

| **Variant** | **Protein Change** | **Domain** | **Functional Effect** | **Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|---|
| c.1999G>A | p.Val667Ile | TMD (M2) | GoF; reduced Mg²⁺ block | Epileptic encephalopathy | Pathogenic |
| c.2002C>T | p.Arg668Cys | TMD (M2) | GoF; increased open probability | Epileptic encephalopathy, intellectual disability | Pathogenic |
| c.2155G>A | p.Gly719Arg | TMD (M3) | GoF; altered gating | Early-onset epilepsy | Pathogenic |
| c.2269C>T | p.Arg757Cys | TMD (M4) | LoF; impaired trafficking | Intellectual disability, autism | Likely pathogenic |
| c.2443G>A | p.Asp815Asn | LBD (S2) | GoF; increased glutamate potency | Epileptic encephalopathy | Pathogenic |
| c.2608C>T | p.Arg870Trp | CTD | LoF; disrupted PDZ binding | Intellectual disability | Likely pathogenic |
| c.3340G>A | p.Glu1114Lys | CTD | Unknown; altered phosphorylation | Neurodevelopmental delay | Uncertain significance |
| c.3925C>T | p.Arg1309Trp | CTD | LoF; disrupted PKC phosphorylation | Intellectual disability, seizures | Pathogenic |

### 4.4 Genotype-Phenotype Correlations

**GoF Mutations in the TMD**: Mutations in the M2 pore loop (e.g., p.Val667Ile, p.Arg668Cys) reduce the voltage-dependent Mg²⁺ block, leading to excessive calcium influx at resting membrane potential. This causes neuronal hyperexcitability and excitotoxicity, manifesting as early-onset epileptic encephalopathy with burst suppression on EEG. Patients often present with infantile spasms, developmental regression, and movement disorders.

**GoF Mutations in the LBD**: Mutations in the LBD (e.g., p.Asp815Asn) increase the potency of glutamate, shifting the dose-response curve to the left. This results in receptor activation at lower glutamate concentrations, producing tonic excitotoxicity. The phenotype is similar to TMD GoF mutations but may show a slightly later onset.

**LoF Mutations**: LoF mutations, particularly those in the CTD, impair receptor trafficking to the cell surface or disrupt scaffolding interactions. These mutations cause haploinsufficiency, reducing the number of functional receptors. The phenotype is characterized by intellectual disability, autism spectrum disorder, and hypotonia, with a lower incidence of severe epilepsy.

### 4.5 Clinical Differentials

The clinical presentation of GRIN2D-NDD overlaps with other neurodevelopmental disorders, necessitating genetic testing for definitive diagnosis:

- **GRIN1-Related Disorder**: Caused by mutations in *GRIN1*; presents with similar epileptic encephalopathy but often includes cortical visual impairment and hyperkinetic movements.
- **GRIN2A-Related Disorder**: Caused by mutations in *GRIN2A*; associated with epilepsy-aphasia spectrum disorders, including Landau-Kleffner syndrome.
- **GRIN2B-Related Disorder**: Caused by mutations in *GRIN2B*; presents with intellectual disability, autism, and epilepsy, but with a higher prevalence of structural brain abnormalities.
- **KCNQ2 Encephalopathy**: Caused by mutations in *KCNQ2* (potassium channel); presents with neonatal seizures and similar EEG findings.
- **SCN1A-Related Disorders**: Caused by mutations in *SCN1A* (sodium channel); includes Dravet syndrome, which shares features of early-onset epilepsy and developmental delay.

### 4.6 Somatic Mutations in Cancer

Emerging evidence implicates somatic *GRIN2D* mutations in tumor biology. Exome sequencing of neuroblastoma samples has identified recurrent somatic mutations in *GRIN2D*, including p.Arg668Cys and p.Val667Ile, which are the same hotspots as germline GoF mutations. These mutations are hypothesized to promote tumor cell proliferation and survival through calcium-dependent activation of the PI3K/Akt pathway.

In glioblastoma, *GRIN2D* expression is significantly upregulated compared to normal brain tissue. High expression correlates with poor overall survival and is associated with the mesenchymal subtype. Mechanistically, GluN2D-containing NMDARs in glioma cells mediate calcium influx that activates the NF-κB pathway, promoting the expression of pro-inflammatory cytokines and matrix metalloproteinases that facilitate invasion.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of NMDAR Signaling

Several neurotropic viruses interact with NMDAR signaling pathways, and emerging evidence suggests specific interactions with GluN2D-containing receptors:

**Herpes Simplex Virus Type 1 (HSV-1)**: HSV-1 infection of neurons induces the expression of the viral protein ICP0, which has been shown to interact with PSD-95 and disrupt NMDAR clustering. While direct binding to GluN2D has not been demonstrated, the disruption of PSD-95-mediated scaffolding would affect GluN2D localization and function. HSV-1 infection also causes calcium dysregulation, which may be exacerbated by GluN2D-mediated tonic currents.

**Human Immunodeficiency Virus Type 1 (HIV-1)**: The HIV-1 envelope glycoprotein gp120 is shed from infected cells and binds to NMDARs, causing excitotoxicity. gp120 has been shown to potentiate NMDAR-mediated calcium influx, and studies using GluN2D-selective antagonists suggest that GluN2D-containing receptors contribute to gp120-induced neurotoxicity in the striatum. This mechanism may underlie HIV-associated neurocognitive disorder (HAND).

**Zika Virus (ZIKV)**: ZIKV infection of neural progenitor cells causes upregulation of *GRIN2D* expression, leading to aberrant calcium signaling and impaired neurogenesis. The mechanism involves viral activation of the innate immune response, which induces NF-κB binding to the *GRIN2D* promoter.

**Rabies Virus**: Rabies virus infection alters NMDAR subunit expression in the brainstem, with a specific reduction in GluN2D levels. This downregulation may contribute to the neuronal dysfunction observed in rabies encephalitis.

### 5.2 Bacterial Toxins

**Botulinum Neurotoxin (BoNT)**: While BoNT primarily targets SNARE proteins, its effects on neurotransmitter release indirectly modulate NMDAR signaling. Chronic BoNT treatment reduces glutamatergic transmission, leading to compensatory upregulation of *GRIN2D* expression in affected neurons.

**Tetanus Toxin**: Similar to BoNT, tetanus toxin cleaves synaptobrevin, reducing neurotransmitter release. Studies in animal models show that tetanus toxin injection increases *GRIN2D* mRNA levels in the spinal cord, potentially contributing to the hyperexcitability observed in tetanus.

### 5.3 Immune Evasion Mechanisms

GluN2D-containing NMDARs have been implicated in neuroinflammation. In autoimmune encephalitis, autoantibodies against NMDARs (primarily targeting the GluN1 subunit) cause receptor internalization and synaptic dysfunction. While GluN2D is not a primary autoantigen, the internalization of GluN1/GluN2D receptors contributes to the clinical syndrome. Additionally, inflammatory cytokines such as TNF-α and IL-1β upregulate *GRIN2D* expression in astrocytes, where GluN2D-containing receptors may mediate calcium waves that propagate neuroinflammation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs Modulating NMDARs

Currently, no FDA-approved drugs selectively target GluN2D-containing receptors. However, several approved drugs modulate NMDARs non-selectively and have relevance to GRIN2D-related disorders:

| **Drug** | **Mechanism** | **Approved Indication** | **Relevance to GRIN2D** |
|---|---|---|---|
| Memantine | Non-competitive NMDAR antagonist; use-dependent open-channel blocker | Alzheimer's disease | Blocks GluN2D-containing receptors with moderate affinity; may be repurposed for GoF GRIN2D mutations |
| Ketamine | Non-competitive NMDAR antagonist | Depression (esketamine); anesthesia | Blocks all NMDAR subtypes; used off-label for treatment-resistant depression |
| Dextromethorphan/Quinidine (Nuedexta) | NMDAR antagonist; sigma-1 agonist | Pseudobulbar affect | Non-selective NMDAR antagonism |
| Amantadine | NMDAR antagonist | Parkinson's disease; influenza | Weak NMDAR antagonist; may modulate GluN2D in the basal ganglia |

### 6.2 Investigational GluN2D-Selective Compounds

The development of GluN2D-selective modulators is an active area of research, driven by the potential therapeutic applications in neurodevelopmental disorders, Parkinson's disease, and neuropathic pain:

**GluN2D-Selective Antagonists**:

- **PPDA ([(R)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid])**: A competitive antagonist with ~10-fold selectivity for GluN2C/GluN2D over GluN2A/GluN2B. Used extensively in electrophysiological studies to isolate GluN2D-mediated currents.
- **QE58**: A use-dependent antagonist with selectivity for GluN2C/GluN2D. Blocks the open channel with slow kinetics.
- **CIQ**: A negative allosteric modulator with selectivity for GluN2C/GluN2D. Binds to the ATD-LBD interface and stabilizes the closed state.

**GluN2D-Selective Positive Allosteric Modulators (PAMs)**:

- **CIQ (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone)**: A PAM that selectively potentiates GluN2C/GluN2D-containing receptors. CIQ increases the open probability and slows deactivation, enhancing tonic NMDA currents.
- **DQP-1105**: A PAM with selectivity for GluN2C/GluN2D; enhances receptor function by increasing agonist potency.

### 6.3 Repurposing Strategies for GRIN2D-NDD

For gain-of-function mutations in *GRIN2D*, the therapeutic goal is to reduce excessive NMDAR activity. Memantine, which is an open-channel blocker with strong voltage-dependence, may preferentially block tonically active GluN2D receptors while sparing phasic synaptic transmission. Case reports and small case series have shown that memantine reduces seizure frequency and improves cognitive function in some patients with GRIN2D GoF mutations.

For loss-of-function mutations, the therapeutic goal is to enhance receptor function. D-serine, a co-agonist at the glycine site, has been shown to potentiate NMDAR function and is being investigated in clinical trials for GRIN-related disorders. However, the efficacy of D-serine in LoF GRIN2D mutations depends on the specific mutation; mutations that impair glutamate binding may not respond to co-agonist potentiation.

### 6.4 Gene Therapy Approaches

**Antisense Oligonucleotides (ASOs)**: For GoF mutations, allele-specific ASOs can selectively degrade mutant *GRIN2D* mRNA while sparing the wild-type allele. This approach has been successfully applied to *GRIN2B* mutations in preclinical models and is being adapted for *GRIN2D*.

**CRISPR/Cas9 Gene Editing**: For dominant-negative LoF mutations, CRISPR-mediated gene correction could restore wild-type function. However, the delivery challenges and off-target effects limit current clinical applicability.

**Adeno-Associated Virus (AAV) Vectors**: AAV-mediated delivery of the wild-type *GRIN2D* cDNA is being explored for LoF mutations. The challenge is achieving sufficient expression levels and appropriate cell-type specificity, as GluN2D must be expressed in the correct neuronal populations to form functional receptors.

### 6.5 Pharmacogenomic Considerations

The *GRIN2D* gene exhibits genetic variation that may influence drug response:

- **rs1806205 (p.Arg870Trp)**: This LoF variant is present in ~1% of the population and is associated with reduced NMDAR function. Individuals carrying this variant may show altered responses to NMDAR antagonists, including reduced efficacy of ketamine for depression.
- **rs2229276 (p.Val667Ile)**: This GoF variant is rare in the general population but enriched in patients with epilepsy. Carriers may be more sensitive to the neurotoxic effects of NMDAR overactivation and may benefit from memantine therapy.
- **Promoter Methylation**: Inter-individual variation in *GRIN2D* promoter methylation affects baseline expression levels, potentially influencing susceptibility to excitotoxicity and response to NMDAR-targeting drugs.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and links for *GRIN2D*:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 4587 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4587 |
| NCBI Gene | 2906 | https://www.ncbi.nlm.nih.gov/gene/2906 |
| Ensembl | ENSG00000173085 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173085 |
| UniProt | O15399 | https://www.uniprot.org/uniprotkb/O15399 |
| RCSB PDB | 6IRA | https://www.rcsb.org/structure/6IRA |
| ClinVar | GRIN2D | https://www.ncbi.nlm.nih.gov/clinvar/?term=GRIN2D |
| OMIM | 602717 | https://www.omim.org/entry/602717 |
| gnomAD | ENSG00000173085 | https://gnomad.broadinstitute.org/gene/ENSG00000173085 |
| STRING | O15399 | https://string-db.org/network/9606.ENSP00000361859 |
| BioGRID | 112690 | https://thebiogrid.org/112690 |
| Gene Ontology (GO) | GO:0004972 (NMDAR activity); GO:0005230 (extracellular ligand-gated ion channel activity); GO:0005886 (plasma membrane); GO:0035255 (ionotropic glutamate receptor binding) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-438066 (Unblocking of NMDA receptors) | https://reactome.org/content/detail/R-HSA-438066 |
| KEGG | hsa:2906 | https://www.genome.jp/dbget-bin/www_bget?hsa:2906 |
| Human Protein Atlas | ENSG00000173085 | https://www.proteinatlas.org/ENSG00000173085-GRIN2D |
| DECIPHER | GRIN2D | https://www.deciphergenomics.org/gene/GRIN2D |
| LOVD | GRIN2D | https://databases.lovd.nl/shared/genes/GRIN2D |

### Gene Ontology Annotations

| **Ontology Category** | **GO Term** | **Description** |
|---|---|---|

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)